Table 5.
AE, n (%) | Switched patients (n = 84)a |
---|---|
Any AE | 11 (13) |
Maximum intensity of any AE | |
Mild | 8 (10) |
Moderate | 3 (4) |
Any serious AE | 2 (2) |
Deaths | 0 (0) |
AE adverse event, ERA endothelin receptor antagonist, PDE5 phosphodiesterase type 5
aPatients who previously received an ERA, prostacyclin, and/or PDE5 inhibitor, and who stopped this treatment before starting riociguat